Allarity Therapeutics, Inc. (ALLR)

NASDAQ: ALLR · IEX Real-Time Price · USD
0.400
0.00 (0.05%)
Dec 9, 2022 1:46 PM EST - Market closed
0.05%
Market Cap 4.10M
Revenue (ttm) n/a
Net Income (ttm) -34.63M
Shares Out 9.87M
EPS (ttm) -3.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,537
Open 0.4
Previous Close 0.4
Day's Range 0.366 - 0.424
52-Week Range 0.361 - 18.2
Beta 0.00
Analysts Sell
Price Target 5.10 (+1,260.0%)
Earnings Date Aug 26, 2022

About ALLR

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of ... [Read more]

Industry Biotechnology
Founded 2004
Employees 13
Stock Exchange NASDAQ
Ticker Symbol ALLR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ALLR stock is "Sell." The 12-month stock price forecast is 5.1, which is an increase of 1,260.00% from the latest price.

Price Target
$5.1
(1,260.00% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Rega...

Cambridge, MA U.S.A. ( October 11 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-s...

1 month ago - GlobeNewsWire

Allarity Therapeutics Announces Appointment of New Auditor

Press release

2 months ago - GlobeNewsWire

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

New strategy align s with ongoing shift in oncology standard - of - care towards combination therapies

4 months ago - GlobeNewsWire

Allarity Therapeutics Announces Executive Leadership Transition

Board Appoints James G. Cullem, J.D. , to Interim Chief Executive Officer , Joan Y. Brown, CPA , to Interim Chief Financial Officer

5 months ago - GlobeNewsWire

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili...

Cambridge, MA U.S.A . ( June 15 , 202 2 ) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-s...

5 months ago - GlobeNewsWire

Allarity Therapeutics Reports First Quarter 2022 Financial Results

Cambridge, MA U.S.A. ( May 27 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-speci...

6 months ago - GlobeNewsWire

Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial R...

Cambridge, MA U.S.A. ( May 1 8 , 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Ful...

6 months ago - GlobeNewsWire

Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Cambridge, MA U.S.A. ( May 16 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-speci...

6 months ago - GlobeNewsWire

Allarity Therapeutics Provides Update on Dovitinib Program

FOR IMMEDIATE RELEASE

8 months ago - GlobeNewsWire

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

Press release Cambridge, MA U.S.A . ( February 18 , 202 2 ) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics to...

9 months ago - GlobeNewsWire

Allarity, Oncoheroes Ink Agreements For Pediatric Cancer Programs

Allarity Therapeutics Inc (NASDAQ: ALLR) and Oncoheroes Biosciences Inc have entered into licensing agreements for Allarity's dovitinib and stenoparib for further clinical development in pediatric cance...

11 months ago - Benzinga

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib...

Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics

11 months ago - GlobeNewsWire